Core Viewpoint - Enhua Pharmaceutical has initiated a Class III recall of the Carbamates Tartrate Capsules due to quality management issues identified during an inspection of the manufacturing facility by the National Medical Products Administration (NMPA) [1][2]. Group 1: Recall Details - The recall involves Carbamates Tartrate Capsules, which are used to treat mild to moderate Alzheimer's disease [2]. - The recall is classified as Class III, indicating that while it generally does not pose a health risk, it is necessary for other reasons [2]. - Enhua Pharmaceutical stated that the recall is in compliance with the relevant regulations to ensure medication safety [2]. Group 2: Financial Impact - In 2025, the sales revenue from the recalled product was approximately 40 million yuan, accounting for less than 1% of the company's total revenue [2]. - The estimated sales amount involved in the recall is around 9 million yuan, with the actual quantity and amount of recalled products yet to be determined [2]. - The company plans to reduce its current operating income by the sales amount of the recalled products, which is expected to have a minimal impact on overall revenue [3]. Group 3: Future Measures - Enhua Pharmaceutical intends to strengthen supplier management and improve its quality management system to ensure product quality and patient safety in the future [3].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has decided to suspend the import, sale, and use of the Cabalitin capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies identified during a remote inspection [1][2]. Group 1: Regulatory Actions - The NMPA found that Sun Pharmaceutical's quality management department was inadequate, leading to insufficient risk assessment for certain batches of products that exceeded standards [1] - The suspension will take effect from January 23, 2026, as per relevant regulations [1] - Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., a wholly-owned subsidiary of Enhua Pharmaceutical, will initiate a three-level recall of the affected Cabalitin capsules to ensure medication safety [1] Group 2: Financial Impact - For the fiscal year 2025, the sales revenue from the recalled product is approximately 40 million yuan, accounting for less than 1% of the company's total revenue [2] - The estimated sales amount involved in the recall is around 9 million yuan, with the actual quantity and amount of recalled products yet to be determined [2] - The company anticipates that the recall will not have a significant impact on its production operations or annual financial status, and it plans to strengthen supplier management and quality control systems in the future [2]

Core Viewpoint - The National Medical Products Administration (NMPA) of China has decided to suspend the import, sale, and use of the Cabalitin capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies identified during a remote inspection [1][2]. Group 1: Regulatory Actions - The NMPA found that Sun Pharmaceutical's quality management department was inadequate and failed to conduct sufficient risk assessments for certain batches of products that exceeded standards [1] - The suspension will take effect from January 23, 2026, as per relevant regulations [1] - Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., a wholly-owned subsidiary of Enhua Pharmaceutical, will initiate a three-level recall of the affected Cabalitin capsules to ensure medication safety [1] Group 2: Financial Impact - For the fiscal year 2025, the sales revenue from the recalled product is approximately 40 million yuan, accounting for less than 1% of the company's total revenue [2] - The estimated sales amount involved in the recall is around 9 million yuan, with the actual quantity and amount of recalled products yet to be determined [2] - The company anticipates that the recall will not have a significant impact on its production operations or annual financial status, and it will take legal measures to address any economic losses due to supplier issues [2] Group 3: Future Measures - The company plans to enhance supplier management and improve its quality management system to ensure product quality and maintain patient safety [2]

Core Viewpoint - The National Medical Products Administration (NMPA) has suspended the import, sale, and use of the Cabergoline capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies and non-compliance with China's drug production quality management standards [1][2]. Group 1: Company Response - Enhua Pharmaceutical's wholly-owned subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., is responsible for the sales of the affected Cabergoline capsules in China and has initiated a three-level recall to ensure medication safety [1]. - The company anticipates that the sales revenue from the recalled product for the fiscal year 2025 will be approximately 40 million yuan, accounting for less than 1% of its total revenue [2]. - The estimated sales amount involved in the recall is around 9 million yuan, and the actual quantity and value of the recalled products are currently undetermined [2]. Group 2: Financial Impact - The company expects that the financial impact of the recall will be minimal, as the recalled product's sales amount represents a small proportion of the company's total revenue for the same period [2]. - The company reserves the right to take legal measures to address economic losses resulting from supplier issues, including inventory write-offs and product recalls [2].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has suspended the import, sale, and use of two drugs produced by Indian manufacturers due to quality control issues, impacting the market for Alzheimer's and allergy medications [3][5]. Group 1: Drug Suspension Details - The two suspended drugs are the Cabalistine Tartrate Capsules from Sun Pharmaceutical Industries Limited, used for treating mild to moderate Alzheimer's disease, and the Chlorpheniramine Maleate raw material from Supriya Lifescience Ltd., commonly used in cold medications [3][4]. - Sun Pharmaceutical's Cabalistine Tartrate Capsules were found to have quality management deficiencies, including inadequate risk assessment for batches exceeding standards and failure to prevent contamination during production [3][5]. - Supriya Lifescience's Chlorpheniramine Maleate raw material was suspended due to non-compliance with production quality management standards, including failure to ensure that each batch met regulatory requirements and inadequate facility management [5][6]. Group 2: Impact on the Industry - The suspension of Supriya Lifescience's raw material will not only affect the company but also Chinese pharmaceutical companies that use this raw material in their cold medications [5][6]. - This is not the first instance of Supriya Lifescience's Chlorpheniramine Maleate being suspended; it faced a similar suspension in March 2020 due to non-compliance with production quality management standards [5][6]. - The NMPA has mandated that any formulations produced using the suspended raw material must not be released, and companies must conduct investigations and implement risk control measures for already released products [6].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has suspended the import, sale, and use of two drugs produced by Indian manufacturers due to quality management issues during production, which do not comply with China's drug production quality management standards [1][2]. Group 1: Sun Pharmaceutical Industries Limited - The drug in question is the Cabergoline capsule, used as a first-line treatment for mild to moderate Alzheimer's disease, and is a generic product from Sun Pharmaceutical Industries Limited [1]. - The suspension was due to inadequate quality management capabilities in the production process, insufficient risk assessment for batches exceeding standards, and defects in preventing contamination and compliance with the Chinese Pharmacopoeia [1]. Group 2: Supriya Lifescience Ltd. - Supriya Lifescience Ltd. is one of the top five global manufacturers of Chlorpheniramine Maleate raw materials [2]. - The suspension of Chlorpheniramine Maleate raw materials was due to the company's failure to ensure that each batch of released products met regulatory and registration requirements, along with poor site management and ineffective measures to prevent pests [2]. - This is not the first instance of Supriya Lifescience Ltd.'s raw materials being suspended; a similar suspension occurred in March 2020 due to non-compliance with production quality management standards [2]. Group 3: Regulatory Actions and Implications - The NMPA has mandated that the Chlorpheniramine Maleate raw materials from Supriya Lifescience Ltd. cannot be sold or used for drug formulation in China, and any formulations already produced with these raw materials cannot be released [3]. - The holders of drug marketing licenses for products already on the market must conduct investigations and evaluations immediately and take necessary risk control measures based on the findings [3].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has suspended the import, sale, and use of two drugs produced by Indian manufacturers due to quality management issues during production [1][3]. Group 1: Company-Specific Information - Sun Pharmaceutical Industries Limited's drug, the racemic carbamazepine capsule, is a first-line treatment for mild to moderate Alzheimer's disease and is a generic product [1][3]. - The suspension of Sun Pharmaceutical's product is attributed to inadequate quality management, insufficient risk assessment of certain batches, and failure to comply with China's Good Manufacturing Practice (GMP) standards [3]. - Supriya Lifescience Ltd. is recognized as one of the top five global manufacturers of chlorpheniramine maleate raw materials, which is commonly used in combination cold medications [3]. Group 2: Regulatory Actions and Implications - The NMPA's suspension of Supriya Lifescience Ltd.'s chlorpheniramine maleate raw material is due to the company's failure to ensure compliance with regulatory and registration requirements during production [3][5]. - This is not the first instance of Supriya Lifescience Ltd.'s chlorpheniramine maleate being suspended; a similar suspension occurred in March 2020 due to non-compliance with GMP standards [4]. - The suspension will not only affect Supriya Lifescience Ltd. but also Chinese pharmaceutical companies that utilize this raw material for their cold medications, requiring immediate investigation and risk control measures for already released products [5].

Core Viewpoint - The National Medical Products Administration (NMPA) has suspended the import, sale, and use of the cabozantinib capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies and non-compliance with production standards [1] Group 1: Regulatory Actions - NMPA conducted a remote inspection of Sun Pharmaceutical Industries Limited regarding the cabozantinib capsules [1] - The inspection revealed that the company's quality management department lacked sufficient capability, leading to inadequate risk assessment for certain batches of marketed products [1] - As a result, NMPA has decided to halt the importation, sale, and usage of the cabozantinib capsules immediately [1] Group 2: Compliance Issues - The inspection found defects in the production process related to contamination prevention and adherence to the Chinese Pharmacopoeia [1] - Sun Pharmaceutical Industries Limited's practices were deemed non-compliant with the Drug Production Quality Management Standards (2010 revision) of China [1] - The drug supervision departments at various import ports have been instructed to suspend the issuance of import clearance documents for the affected product [1]

As filed with the Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTRESS BIOTECH, INC. (Exact name of registrant as specified in its charter) Delaware 20-5157386 (State or other jurisdiction of incorporation or organization) 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (Address, including zip code, and telephone number, includ ...

Core Insights - Fortress Biotech's subsidiary Checkpoint Therapeutics has been acquired by Sun Pharmaceutical Industries for $4.10 per share in cash, with additional contingent value rights and royalties tied to future sales of UNLOXCYT™ [1][2] Financial Details - Fortress will receive approximately $28 million shortly after the closing of the transaction and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ [1][2] - The acquisition deal was approved by Checkpoint's stockholders on May 28, 2025, and closed on May 30, 2025 [1][2] Product Information - UNLOXCYT™ (cosibelimab-ipdl) is the first and only FDA-approved PD-L1 blocking antibody for advanced cutaneous squamous cell carcinoma, receiving FDA approval in December 2024 [3] Company Strategy - Fortress Biotech focuses on acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value through product revenue, equity holdings, and dividend and royalty revenue [4] - The company aims to strengthen its balance sheet through opportunistic transactions and is actively evaluating business development opportunities [2][4]